Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC23407 AZ8838 racemate
AZ8838 racemate(AZ-8838 racemate) is the racemate form of AZ8838, which is a potent, and selective PAR2 antagonist with Kd of 125 nM..
More description
DC11742 AZ-8838
AZ-8838 (AZ8838) is a potent, and selective PAR2 antagonist with Kd of 125 nM.
More description
DC12274 AZ82
AZ82 is a selective HSET/KIFC1 inhibitor, with a Ki of 43 nM and an IC50 of 300 nM for KIFC1.
More description
DC10985 AZ6197
AZ6197 (AZ-6197) is a potent, selective, reversible inhibitor of ERK1/2 with IC50 of <0.3 nM (ERK2), inhibits pERK/pRSK with IC50 of 12/62 nM in A375 cells, respectively.
More description
DC20715 AZ-4217
AZ-4217 is a potent and selective, orally active, brain-permeable BACE1 inhibitor with IC50 of 160 pM in human SH-SY5Y cells.
More description
DC23855 AZ-23
AZ-23 is a potent, selective, orally bioavailable Trk kinase inhibitor with IC50 of 2 and 8 nM for TrkA and TrkB, respectively.
More description
DC20315 AZ-2
AZ-2 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity.
More description
DC23484 AZ1729
AZ1729 is a novel direct, positive allosteric modulator of fatty acid receptor FFA2 (pEC50=6.9), selectively activates Gi signaling but lacks the capacity to activate FFA2 Gq/G11-mediated signaling pathways.
More description
DC20713 AZ13711265
AZ13711265 is a potent, selective, in vivo active PAK1 inhibitor with IC50 of 0.58 nM, displays 880-, 2100- and 90-fold selectivity over Src, FGFR1, KDR and PAK4.
More description
DC21406 AZ-1355
AZ-1355 is an effctive lipid-lowering compound that inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro..
More description
DC12531 AZ12799734
AZ12799734 (AZ-12799734) is a pan BMP/TGFβ inhibitor that potently inhibits ligand activated SMAD3/4 transcription with IC50 of 47 nM, inhibits receptor-mediated phosphorylation of SMAD1 by ALK1, BMPR1A and BMPR1B and phosphorylation of SMAD2 by ALK4, TGF
More description
DC12530 AZ12601011
AZ12601011 (AZ-12601011) is a potent, selective inhibitor of ALK4, ALK7 and TGFBR1 (Kd=2.9 nM), inhibits TGFβ-induced reporter activity with IC50 of 18 nM.
More description
DC22724 AZ12441970
AZ12441970 is a selective TLR7 agonist with pEC50 of 6.8 and 6.6 for human and rat TLR7, shows inactivity against TLR8.
More description
DC12613 AZ12204657
AZ12204657 (AZ-12204657) small-molecule GPR44 antagonist, displaces the binding of [3H]PGD2 from membranes of HEK293 cells transfected with human recombinant GPR44 with IC50 of 2.5 nM.
More description
DC11975 AZ 10397767
AZ10397767 is a potent, selective CXCR2 inhibitor that inhibits CXCL8 binding to CXCR2 with pIC50 of 9.0.
More description
DC20314 AZ-1
AZ-1 is a small molecule inducer of ABCA1 and apoE that act through indirect activation of the LXR pathway, shows purinergic receptor P2X7 antagonist activity.
More description
DC11147 AZ084
AZ084 (AZ-084) is a potent, selective, allosteric, orally available CCR8 antagonist with Ki of 0.9 nM.
More description
DC20710 AZ0108
AZ0108 is an orally bioavailable phthalazinone PARP inhibitor with enzyme IC50 of <30/<30/83 nM for PARP1/2/6 respectively.
More description
DC23879 AZ 4800
AZ 4800 is a potent γ-secretase modulator that reduces Aβ40 and Aβ42 levels in HEK/APPswe cells with IC50 of 26 nM and 60 nM, also decreases Aβ39, whereas increases both Aβ37 and Aβ38..
More description
DC20313 Axl-IN-21
Axl-IN-21 is a selective and potent inhibitor of wild-type Axl with IC50 of 2.2 nM.
More description
DC20709 AW-814141
AW-814141 is a potent, selective and orally active inhibitor of p38 MAP kinase with IC50 of 100 nM/158 nM for p38α/p38β.
More description
DC9436 Avosentan
Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist.
More description
DC12715 AVG-233
AVG-233 (AVG233) is a potent, allosteric inhibitor of respiratory syncytial virus (RSV) RNA-dependent RNA polymerase (RdRp) complex, demonstrates nanomolar activity against both laboratory-adapted RSV strains and clinical RSV isolates (EC50=34-79 nM).
More description
DC20703 AVE-0118
AVE-0118 is a potent I(to)/I(Kur) blocker, Kv1.5 channel inhibitor with IC50 of 5.6 uM, also blocks Kv1.3, Kv2.1, Kv3.1, and Kv4.3 channels with similar potency.
More description
DC22012 Avanbulin
Avanbulin (BAL27862, BAL-27862) is a novel microtubule-destabilizing agent that potently inhibits tubulin assembly at 37°C with IC50 of 1.4 uM in tubulin-binding assays.
More description
DC8253 AV-412(MP-412)
AV-412(MP-412) is a potent dual inhibitor of EGFR and ErbB2(IC50=19 nM) tyrosine kinases, including the mutant EGFR(L858R IC50=0.51 nM, T790M IC50=0.79 nM); inhibits autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively.
More description
DC22220 Auxin agonist RN4
Auxin agonist RN4 (RubNeddin 4) is a potent, selective auxin agonist that induces specific AUX/IAA protein degradation to modulate plant development.
More description
DC22219 Auxin agonist RN3
Auxin agonist RN3 (RubNeddin 3) is a potent, selective auxin agonist that induces specific AUX/IAA protein degradation to modulate plant development.
More description
DC20701 Autotaxin inhibitor compound 1
Autotaxin inhibitor compound 1 (Autotaxin-IN-1) is a potent, selective, orally bioavailable inhibitor of autotaxin with IC50 of 2.2 nM in ex vivo human whole blood assay, does not inhibit related proteins ENPP1 and ENPP7.
More description
DC21866 Autotaxin inhibitor 12
Autotaxin inhibitor 12 is a highly potent, selective, orally-bioavailable inhibitor of autotaxin with IC50 of 3.1 nM in choline release assays.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X